390 results about "Smooth muscle" patented technology

The invention discloses a bionic nano-composite, a preparation method thereof and application of the bionic nano-composite in preparation of a product for treating atherosclerosis, and belongs to the technical field of medicine preparation. The bionic nano compound is a metal nano enzyme Ir-TiO2 coated by an M2 macrophage cell membrane. According to the invention, the surfaces of Ir-TiO2 nanoparticles are coated with M2 macrophage membranes, so that the nanocomposite with a bionic structure is prepared. After intravenous injection, the formed bionic nanocomposite can actively target endothelial cells in atherosclerotic lesions, and release Ir-TiO2 antagonism to endothelial cells in plaques and cytoplasm of inflammatory macrophages. After the Ir-TiO2 reaches the diseased region, the Ir-TiO2 can play an enzyme role to achieve an anti-inflammatory effect, and can promote inflammatory cells such as macrophages and smooth muscle cells at the diseased region to discharge cholesterol, reduce lipid deposition in the cells, reduce the generation of foam cells and promote the growth of plaques. The nanotherapy can effectively prevent the progress of atherosclerosis lesion inflammation and relieve atherosclerosis.

The invention discloses a stem cell exosome based on targeted fusion polypeptide modification, a preparation method and application of the stem cell exosome in treating male erectile dysfunction. According to the exosome, a specific targeting fusion polypeptide (sequence: EPLQLKM-GGGS-DPPV) is anchored on the surface through a chemical coupling technology, so that the targeting property of the exosome on cavernosum smooth muscle cells is enhanced; meanwhile, an anti-TrkA monoclonal antibody (TrkA-2E7-HL) is loaded through an electroporation method, and a fibrosis pathway mediated by a nerve growth factor (NGF) is inhibited. The exosome induces secretion of the umbilical cord mesenchymal stem cells by adopting an anti-oxidation culture medium, so that the anti-oxidation activity of the exosome is remarkably improved. Experiments show that in a diabetes ED rat model, the erectile function (ICP / MAP ratio) of the modified exosome is improved to 0.79 + / -0.05, the fibrosis area is reduced to 9.2 + / -1.6%, and the NO secretion level is improved by 3.5 times compared with that of a common exosome. Through triple mechanisms of polypeptide targeting, antibody synergy and oxidation resistance, effective reversion of the ED pathological process is realized, and the polypeptide has remarkable novelty and clinical transformation potential.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, those within the respiratory tract, particularly the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The systems may be used to treat pathogens, such as bacteria and viruses, particularly coronaviruses.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

The invention discloses application of decitabine in preparation of a medicine for resisting vascular calcification, and belongs to the technical field of medical biology. A CKD mouse vascular calcification model is constructed through combination of 5 / 6 nephrectomy and high phosphorus diet (5 / 6NX), and it is observed that the expression level of DNMT3A in model mouse calcified blood vessels is remarkably increased, and the DNA methylation degree is remarkably increased. Based on this, people try to use decitabine to reduce the expression of DNMT, and discover that intraperitoneal injection of decitabine inhibits the expression of DNMT3A in CKD artery blood vessels and osteogenesis-like transdifferentiation of vascular smooth muscle cells, so that CKD-related vascular calcification is effectively relieved.

Apparatus and methods for deactivating bronchial nerves and ablating smooth muscle extending along a bronchial branch of a mammalian subject to treat asthma and related conditions. An ultrasonic transducer (11) is inserted into the bronchus as, for example, by advancing the distal end of a catheter (10) bearing the transducer into the bronchial section to be treated. The ultrasonic transducer emits ultrasound so as to heat tissues throughout a relatively large impact volume (13) to a temperature sufficient to inactivate nerve conduction and ablate smooth muscle but insufficient to cause rapid ablation or necrosis of the surrounding tissues. The treatment can be performed without locating or focusing on individual bronchial nerves or smooth muscle.

The invention relates to an application of a histone H3K18 lactic acid modification related target in preparation of a medicine for preventing or treating atherosclerosis. The invention belongs to the field of biological medicine, and discloses histone acetyltransferase P300 and application of histone H3K18 lactylation (H3K18la) modification mediated by the histone acetyltransferase P300 as a new target spot for treating atherosclerosis (AS). Researches find that in the AS process, lactic acid accumulation in vascular smooth muscle cells (VSMCs) up-regulates H3K18la through P300 catalysis, and then the pathological phenotype of the VSMCs is induced, and plaque development is promoted. H3K18la can be reduced and the phenotype can be improved by inhibiting LDHA and MCT1 in vitro or knocking out a P300 gene; the P300 for in-vivo targeted inhibition of the VSMCs can significantly reduce the artery plaque. Therefore, the P300 and H3K18la inhibitors can be used for preparing the anti-atherosclerosis medicine.

Provided herein are optionally substituted pyrazolylacetamides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating diseases or disorders, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania, tinnitus, neurodevelopmental diseases or disorders, a smooth muscle contractility disorder, Dravet syndrome, posttraumatic stress disorder (PTSD), with such compounds and pharmaceutical compositions.

The invention discloses shRNA (short hairpin Ribonucleic Acid) for targeted knockout of an Eif2ak2 gene and application, and belongs to the technical field of gene engineering. The shRNA comprises a positive-sense strand and an antisense strand which is reversely complementary with the positive-sense strand, and the nucleotide sequence of the positive-sense strand is shown as SEQ ID NO. 5. It is found for the first time that the recombinant adeno-associated virus capable of inhibiting Eif2ak2 gene expression can successfully inhibit the phenotype of the abdominal aortic aneurysm of a mouse, obviously reduce the morbidity of the abdominal aortic aneurysm of the mouse, improve the severity of the abdominal aortic aneurysm of the mouse, reduce the inner diameter of a blood vessel and the ratio of the weight to the body weight of the blood vessel, and promote the contraction function of vascular smooth muscle cells of the mouse; the method can be used for effectively treating the abdominal aortic aneurysm, provides a new thought and strategy for treating the abdominal aortic aneurysm, and has a wide clinical application prospect.

The present invention relates to methods for obtaining induced smooth muscle cells (iSMCs), iSMCs, iSMCs for use in a method of treating a disease or disorder or for use in tissue engineering, and the use of skeletal muscle derived cells for obtaining iSMCs.

The invention belongs to the field of biological medicine, and particularly relates to application of deaminotyrosine in preparation of a medicine for treating vascular calcification symptoms. The invention finds that deaminotyrosine can significantly reduce the vascular calcification degree of an in-vitro cell model and an in-vivo animal model by inhibiting osteogenic differentiation and calcium salt deposition of vascular smooth muscle cells; therefore, the invention provides a new application of the deaminated tyrosine or pharmaceutically acceptable salt, ester, solvate or prodrug thereof in preparation of drugs for treating vascular calcification symptoms. The invention also provides a pharmaceutical composition, which takes deaminated tyrosine as an active component, and provides a brand new drug choice for clinical prevention and treatment of vascular calcification.

The invention discloses a galiaceae-euphorbia tripsacus compound extract as well as a preparation method and vagina repair application thereof. The compound extract is prepared from galiaceae herbs and euphorbia tripsacus according to a scientific ratio through compound enzymolysis pretreatment, gradient ethanol solvent step-by-step extraction and double-resin series purification. According to the preparation method, the dissolution rate of the active components is remarkably increased by utilizing an enzymolysis wall breaking technology, the problem that the purity of the multi-polar components (tannin, flavone and polysaccharide) is difficult to increase and extract at the same time is solved through gradient extraction and series purification, and the purity of the total active components is more than or equal to 60%. The obtained composite extract has multiple effects of astringing and tightening, promoting regeneration of elastic fibers and improving contractility of smooth muscles, and is safe and non-irritant. The invention further discloses targeted sustained-release gel containing the extract, and the targeted sustained-release gel can be used for improving vaginal relaxation and deeply repairing private parts.

The invention discloses application of salvianolic acid A in preparation of a medicine for preventing and treating vulnerable plaques of advanced atherosclerosis. The invention also discloses application of the salvianolic acid A combined with ferulic acid or the salt thereof in preparation of drugs for preventing and treating advanced atherosclerosis vulnerable plaques. Researches find that salvianolic acid A can promote apoptosis of senescent vascular smooth muscle cells and has a Senlytics effect; the salvianolic acid A stabilizes vulnerable atherosclerotic plaques by reducing the load of senescent vascular smooth muscle cells; the salvianolic acid A is in non-covalent binding with ASP54, ALA55, LYS58, ASP93, ASP102 and LYS112 of the HSP90AA1 to play a role in inhibition, and the ASP93 has the greatest contribution to binding free energy. The research of the invention is of great significance to the development and application of drugs with anti-aging effect for stabilizing advanced atherosclerotic vulnerable plaques.

Provided herein are optionally substituted pyrazolylacetamides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating diseases or disorders, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania, tinnitus, neurodevelopmental diseases or disorders, a smooth muscle contractility disorder, Dravet syndrome, posttraumatic stress disorder (PTSD), with such compounds and pharmaceutical compositions.

The invention provides a balloon catheter system which comprises a balloon catheter with a balloon and a restraining support, the outer surface of the balloon is provided with a concave part, the restraining support is arranged outside the balloon and comprises a restraining part, and when the interior of the balloon reaches preset pressure and is in an expansion state, the restraining part is used for restraining the balloon. The restraining part makes contact with the outer surface of the balloon and limits radial expansion of the balloon in the contact area of the restraining part and the outer surface of the balloon, the concave part and the restraining part are matched to form a plurality of protruding parts on the surface of the balloon, the protruding parts can extrude the narrow section of the blood vessel, atheromatous substances, arterial plaques and the like of the narrow section are extruded to deform and attached to the inner wall of the blood vessel, and therefore the blood vessel is protected. And a good blood vessel expansion effect is achieved. Meanwhile, the concave areas are formed among the convex parts, extruded atheromatous substances, artery plaques and the like can move towards the concave areas among the convex parts nearby, part of extruded force is released, and the situation that the blood vessels are damaged due to the fact that smooth muscles of the blood vessel walls are torn too much is avoided.

The invention discloses a functional coating, an intravascular stent and a preparation method and application of the intravascular stent. The functional coating comprises an endothelialization promoting active substance and an anti-proliferation drug; the endothelialization promoting active substance comprises at least one of polypeptide containing an RGD sequence, polypeptide containing a YIGSR sequence, polypeptide containing an REDV sequence, a beta-polypeptide polymer or a beta-polypeptide-polyester block copolymer. The functional coating disclosed by the invention can be used for surface functional modification of interventional medical devices, can selectively promote adhesion and proliferation of vascular endothelial cells at an implantation part, realizes rapid endothelialization, and can controllably release an anti-proliferation drug to inhibit excessive proliferation of vascular smooth muscle cells, so that the vascular endothelial cells are prevented from being damaged. Therefore, the risks of restenosis and advanced thrombus are effectively reduced.

The invention relates to a phenylacetylglutamine / phenylacetylglycine induced vascular smooth muscle cell senescence model and an establishment method and application thereof, and belongs to the technical field of cell models.The method comprises the following steps that vascular smooth muscle cell suspension is placed in a porous plate, 10% of FBS and 1% of mycillin are added into a culture medium, 24 h after cells adhere to the wall, the vascular smooth muscle cell senescence model is obtained, and the vascular smooth muscle cell senescence model is obtained. The method comprises the following steps of: adding a proper amount of phenylacetyl glutamine or phenylacetyl glycine dimethyl sulfoxide solution into a porous plate, changing a serum-free culture medium, continuously culturing for 24 hours, adding a proper amount of phenylacetyl glutamine or phenylacetyl glycine dimethyl sulfoxide solution into the porous plate, changing the culture medium added with phenylacetyl glutamine or phenylacetyl glycine once every 24 hours, and collecting cells after 72 hours. According to the invention, phenylacetylglutamine / phenylacetylglycine is used for inducing and establishing the vascular smooth muscle cell senescence model for the first time, the method is easy to operate and low in cost, and a foundation is laid for researching the relationship between cardiovascular diseases and senescence.

The present invention relates to the technical field of arteriovenous fistulas. Provided is an optimized scheme for postoperative vasodilation of an autologous arteriovenous fistula. The optimized scheme comprises microwave and electromagnetic field stimulation, ultrasonic monitoring and AI analysis, nano-drug sustained-release technology and intelligent pressure regulation. A microwave and electromagnetic field module stimulates vascular smooth muscle by means of precisely controlling a frequency and an intensity; an ultrasound monitoring module collects real-time data on a vascular inner diameter and a blood flow volume; an AI module dynamically adjusts a stimulation intensity on the basis of the data; a nanoparticle sustained-release system realizes long-acting drug release; and a pressure regulation module automatically regulates, by means of a closed-loop control algorithm, external pressure applied to blood vessels. The problems of imprecise physical stimulation, unsustained pharmaceutical support, fixed pressure regulation, etc., in traditional management of postoperative vasodilation are effectively solved.

Provided herein are optionally substituted pyrazolylacetamides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating diseases or disorders, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania, tinnitus, neurodevelopmental diseases or disorders, a smooth muscle contractility disorder, Dravet syndrome, posttraumatic stress disorder (PTSD), with such compounds and pharmaceutical compositions.

The invention discloses an application of 4-octyl itaconic acid (4-OI) in preparation of a medicine for improving pulmonary arterial hypertension (PAH). In-vivo experiments show that 4-OI can significantly reduce pulmonary vascular wall thickening and collagen deposition of a PAH rat model, and effectively improve PAH and vascular remodeling. In-vitro experiments further reveal that 4-OI reduces endoplasmic reticulum stress (ERS) by inhibiting a PERK-eIF2alpha pathway, further blocks SM22 dependent smooth muscle cell phenotypic transformation and endothelial-mesenchymal transformation (EndMT) processes, finally inhibits vascular remodeling, and plays a role in treating PAH. The three key pathological processes of ERS, EndMT and vascular remodeling are closely linked, a new perspective is provided for deeply understanding the correlation among oxidative stress, endothelial dysfunction and vascular structure change in PAH, meanwhile, a theoretical foundation is laid for developing PAH and vascular remodeling accurate treatment drugs, and clinical transformation value is achieved.

The application provides an active exosome stent coating, a vascular stent and a preparation method and application, and belongs to the technical field of biomedical intervention instruments. The active exosome stent coating of the application adopts stem cell-derived myocardial cell active exosomes which are strengthened by active components of traditional Chinese medicine. Compared with commercial myocardial cells, the stem cell-derived myocardial cells have more significant effects of promoting blood vessels and tissue repair and regeneration, and stronger cytokine secretion capacity. The preparation method of the active exosome stent coating of the application adjusts the introduction sequence and premixing mode of active components such as exosomes and drugs, and enhances the homogeneity and stability. The vascular stent prepared by using the active exosome stent coating of the application has reasonable sequential release kinetics design, can realize precise targeted regulation on human coronary artery smooth muscle cells (HCASMC) in vitro, does not affect the repair potential of endothelial cells, and solves the contradiction between traditional stents in terms of "anti-proliferation and promotion of healing".

The invention belongs to the technical field of medicines, and particularly relates to application of sophora alcohol T in preparation of an anti-hepatic fibrosis medicine. The invention provides the application of the sophora alcohol T in preparation of the anti-hepatic fibrosis medicine for the first time, for example, the sophora alcohol T can be applied to preparation of the medicine for preventing or treating hepatic fibrosis. The compound can be used for preparing medicines for inhibiting hepatic stellate cell proliferation or activation, inhibiting fibronectin level rise, inhibiting alpha-smooth muscle actin level rise or inhibiting I-type collagen level rise, and has good patent medicine potential and wide development, transformation and clinical application value and prospect, and the compound can be used for preparing medicines for inhibiting hepatic stellate cell proliferation or activation, inhibiting fibronectin level rise, inhibiting alpha-smooth muscle actin level rise or inhibiting I-type collagen level rise.

The invention provides application of retinoic acid in preparation of a medicine for treating vascular calcification, and belongs to the technical field of medicines. The early warning and treatment effects of retinoic acid on vascular calcification are provided for the first time, a new source is provided for preparing the medicine for early warning and / or treating vascular calcification, and meanwhile the new medicinal value of retinoic acid is explored. Cardiovascular calcification and vascular smooth muscle cell calcification are relieved by supplementing retinoic acid in vivo and in vitro, and the feasibility that retinoic acid can be used as a potential medicine for treating vascular calcification is prompted. The retinoic acid content is in negative correlation with the coronary artery calcification integral of the human body and the calcification severity degree, and it is prompted that the retinoic acid content can serve as an early warning index of cardiovascular calcification and the severity degree.

The generation of complex organ tissues from human embryonic and pluripotent stem cells (PSCs) remains a major challenge for translational studies. It is shown that PSCs can be directed to differentiate into intestinal tissue in vitro by modulating the combinatorial activities of several signaling pathways in a step-wise fashion, effectively recapitulating in vivo fetal intestinal development. The resulting intestinal “organoids” were three-dimensional structures consisting of a polarized, columnar epithelium surrounded by mesenchyme that included a smooth muscle-like layer. The epithelium was patterned into crypt-like SOX9-positive proliferative zones and villus-like structures with all of the major functional cell types of the intestine. The culture system is used to demonstrate that expression of NEUROG3, a pro-endocrine transcription factor mutated in enteric anendocrinosis is sufficient to promote differentiation towards the enteroendocrine cell lineage. In conclusion, PSC-derived human intestinal tissue should allow for unprecedented studies of human intestinal development, homeostasis and disease.

The invention discloses application of gynostemma pentaphyllum polysaccharide to prevention of vascular wall thickening caused by space microgravity and a medicine, the gynostemma pentaphyllum polysaccharide is applied to prevention of vascular wall thickening caused by space microgravity and the medicine for prevention of vascular wall thickening caused by space microgravity, and the medicine contains the gynostemma pentaphyllum polysaccharide; the gynostemma pentaphyllum polysaccharide reduces thickening of blood vessel walls by inhibiting proliferation and migration of vascular smooth muscle cells, can be used for preventing or treating aorta blood vessel wall thickening caused by space microgravity, and is suitable for health guarantee of astronauts in long-term space missions.

The invention belongs to the technical field of molecular biology diagnosis and treatment, and relates to application of a reagent for detecting or inhibiting FN1 and a product for diagnosing or preventing and treating vascular restenosis. The expression level of the FN1 in a vascular restenosis sample is remarkably increased, and the FN1 can promote phenotypic transformation of vascular smooth muscle cells (VSMC). Meanwhile, further research proves that the FN1 has better diagnosis efficiency on the diagnosis of the vascular restenosis, and is higher in sensitivity, specificity and accuracy, so that the FN1 can be used for effectively diagnosing the vascular restenosis. In addition, in-vivo experiments prove that VSMC phenotypic transformation can be inhibited and vascular restenosis can be improved by inhibiting FN1 expression. The invention provides a new direction for research and development of vascular restenosis related diagnosis and prevention and treatment products, and has a good clinical application prospect.

The invention relates to the technical field of traditional Chinese medicines, in particular to application of a traditional Chinese medicine composition in preparation of medicines for preventing and treating hypertension. The traditional Chinese medicine composition comprises sedum sarmentosum, seaweed, oyster, hawthorn, herba siegesbeckiae, schisandra chinensis and polygonum cuspidatum. The composition is found to be capable of remarkably inhibiting a renin-angiotensin-aldosterone system, regulating vascular active factors, relaxing vascular smooth muscles, protecting vascular endothelial functions, reducing heart left ventricular hypertrophy and effectively reducing systolic pressure and diastolic pressure. The traditional Chinese medicine composition is an existing Chinese patent medicine, medication is safe, and the preparation method is simple, rapid, efficient and easy to operate. The prepared mixture, tablet, capsule, pellet and the like are convenient to carry and take.

The invention relates to a preparation method and application of novel rhizoma bletillae glucomannan. The preparation method of the rhizoma bletillae glucomannan comprises the following steps: 1, drying, crushing and sieving rhizomes of a raw material rhizoma bletillae; 2, putting the crushed and sieved rhizoma bletillae into ethanol for degreasing; 3, obtaining crude polysaccharide through a distilled water ice bath ultrasonic extraction technology and an ethanol precipitation technology; 4, separating and purifying through a DEAE-52 cellulose column and a G-150 gel column to obtain the high-purity rhizoma bletillae homogeneous polysaccharide BsPsIII1-1, namely the rhizoma bletillae glucomannan; 5, carrying out semipermeable membrane dialysis on the BsPsIII1-1 to remove salt, and carrying out freeze drying; and 6, carrying out chemical analysis on the obtained BsPsIII1-1. According to the preparation method and the application of the novel rhizoma bletillae glucomannan, animal experiments show that BsPsIII1-1 can significantly improve CCl4 induced mouse liver tissue injury, reduce serum ALT and AST levels, effectively relieve oxidative stress by reducing MDA content and increasing GSH level, and significantly inhibit hepatic fibrosis by down-regulating expression of alpha smooth muscle actin (alpha-SMA) and collagen I (COL-1).

The invention discloses an application of senkyunolide I in preparation of a medicine for treating hepatic fibrosis, which can obviously inhibit HSC (hepatic stellate cell) activation in vitro and evaluate the treatment effect of senkyunolide I on hepatic fibrosis in vivo by adopting a C57BL / 6 mouse hepatic fibrosis model induced by CCl4. The expression levels of liver alpha-smooth muscle actin, type I collagen and matrix metalloproteinase tissue inhibition factor 1 of individuals needing anti-hepatic fibrosis are obviously reduced in vivo and in vitro, and the hepatic fibrosis progress can be effectively intervened. Therefore, according to the application of the senkyunolide I in the hepatic fibrosis, the provided compound senkyunolide I has huge potential for inhibiting the hepatic fibrosis, an effective traditional Chinese medicine monomer component medicine is provided for treating the hepatic fibrosis, the new clinical adaptation application of the senkyunolide I is expanded, and the application prospect is good.

A phosphodiesterase type 5 inhibitor is used in the preparation of a medicament for resisting fibrotic diseases. Experiments in animal models of ischemia-reperfusion (UIRI)-induced renal fibrosis, unilateral ureteral obstruction (UUO)-caused kidney fibrosis and idiopathic pulmonary fibrosis show that a PDE5 inhibitor such as tadalafil, sildenafil and vardenafil can significantly inhibit the expression of multiple fibrosis iconic proteins such as fibronectin, collagen I, renal injury molecule-1, and α-skeletal muscle actin in UIRI and UUO renal fibrosis lesions, improves glomerulopathy, degree of renal tubular distension, renal interstitial collagen fiber deposition and inflammatory cell infiltration, reduces the fibrotic area within the lesion, and significantly inhibits the progression of renal fibrosis; and the PDE5 inhibitor can significantly improve smooth muscle proliferation and inflammatory cell infiltration in bronchioles and pulmonary arterioles of idiopathic pulmonary fibrosis lesion, improve damage condition of alveolar tissue, and significantly inhibit the progression of pulmonary fibrosis.